Build Generational Wealth with
AlphaMadera's AI-Driven Investment Intelligence

Institutional-grade analytics, real-time data, and AI research tools — built for investors who think in decades, not days.

Ask Compass anything about the market — earnings, filings, or strategy — in plain English.

Real-time institutional data AI that reads filings & transcripts Built for decades, not days
or search any ticker above
Editorial illustration: PRIMARY SUBJECT — this editorial photo illustrates a story about Moderna, Inc., a Biotechnology company in the Healthcar
AlphaBlog

Moderna’s Flu Win Reopens the mRNA Question

The first FDA approval of an mRNA flu vaccine gives Moderna a real regulatory win beyond COVID. The market implication is larger than one stock: platform biotech now has to prove it can be a business, not just a technology demo.

Read more →

Market News

MetLife's Q2 Earnings Beat Reaffirms The Buy Case As Organic Growth Stands Out

MetLife's Q2 Earnings Beat Reaffirms The Buy Case As Organic Growth Stands Out

MetLife, Inc. is reaffirmed as a Buy, with quality fundamentals, strong organic growth, and a resilient dividend profile supporting continued bullish momentum. MET's diversified business model, including investment management and group benefits, drives organic growth across multiple segments despite modest profit margin expansion. The balance sheet boasts A-level credit ratings and modest leverage, but significant fixed-income exposure introduces interest rate risk, warranting ongoing monitoring.

Aug 06, 2026 10:44 AM seekingalpha.com

Stock News